Paclitaxel Serum Concentrations Linked to Severity of Neuropathy in Breast Cancer Patients

Video

This video highlights a study that examined whether systemic paclitaxel concentrations in breast cancer patients were associated with severity and progression of chemotherapy-induced peripheral neuropathy.

In this video, N. Lynn Henry, MD, PhD, of the University of Utah Huntsman Cancer Institute, discusses a 60-patient study that examined whether systemic paclitaxel concentrations in breast cancer patients were associated with severity and progression of chemotherapy-induced peripheral neuropathy.

Henry was one of the coauthors of the study (abstract P6-11-03), which was presented during a poster session at the 2017 San Antonio Breast Cancer Symposium (SABCS).

Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Related Content
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

Anthony Zisa;Marcelo Sleiman Jr;Muriel Statman;Duye Liu;Adina Fleischmann;Kenneth Tercyak
July 16th 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Immunotherapy, Novel Agents May Reshape the Early Breast Cancer Landscape

Immunotherapy, Novel Agents May Reshape the Early Breast Cancer Landscape

Ariana Pelosci
July 15th 2025
Article

Heather McArthur, MD, focused on current and future strategies for treating early-stage breast cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD, PhD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys

5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys

Cyrus Yoshimoto
July 13th 2025
Article
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life

6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life

Muriel Statman;Marcelo Sleiman Jr;Duye Liu;Anthony Zisa;Adina Fleischmann;Kenneth Tercyak
July 12th 2025
Article